Loading...
OTCM
IPIX
Market cap159kUSD
Jul 18, Last price  
0.00USD
1D
0.00%
1Q
50.00%
Jan 2017
-99.97%
IPO
-99.85%
Name

Innovation Pharmaceuticals Inc

Chart & Performance

D1W1MN
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
28.47%
Rev. gr., 5y
%
Revenues
0k
-100.00%
000000733,4380000000423,000018,0000
Net income
-3m
L-55.76%
-34,122-47,161-510,193-1,485,331-3,433,400-5,938,297-4,894,402-3,224,482-8,247,000-13,145,000-12,852,000-15,536,000-16,362,000-9,071,000-7,010,000-18,729,000-7,161,000-3,168,000
CFO
-2m
L-66.46%
-622-5,911-80,500-211,480-1,109,293-735,703-693,859-1,907,490-7,510,000-13,071,000-9,887,000-11,711,000-13,278,000-6,332,000-4,156,000-9,495,000-6,280,000-2,106,000

Profile

Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. Its lead drug candidate is Brilacidin, a therapeutic for the treatment of oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. The company is also developing Kevetrin, an anti-cancer compound for treating ovarian cancer. It has a license agreement with Alfasigma S.p.A.; and collaborative research agreement with Fox Chase Chemical Diversity Center, Inc. The company was formerly known as Cellceutix Corporation and changed its name to Innovation Pharmaceuticals Inc. in June 2017. Innovation Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Wakefield, Massachusetts.
IPO date
Apr 02, 2007
Employees
4
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑06
Income
Revenues
Cost of revenue
2,431
Unusual Expense (Income)
NOPBT
(2,431)
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
(2,431)
Net income
(3,168)
-55.76%
Dividends
(86)
Dividend yield
0.85%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
268
Long-term debt
512
Deferred revenue
Other long-term liabilities
Net debt
(4,544)
Cash flow
Cash from operating activities
(2,106)
CAPEX
(60)
Cash from investing activities
(60)
Cash from financing activities
(123)
FCF
132
Balance
Cash
1,518
Long term investments
3,806
Excess cash
5,324
Stockholders' equity
(125,273)
Invested Capital
128,037
ROIC
ROCE
EV
Common stock shares outstanding
505,767
Price
0.02
-35.48%
Market cap
10,115
-35.24%
EV
5,571
EBITDA
(2,058)
EV/EBITDA
Interest
57
Interest/NOPBT